The US venture capital industry continued to contract in the first quarter of the year, new data from Dow Jones VentureSource shows. Venture capitalists invested just $3.90 billion in US companies in the quarter, a 50% decline from the nearly $7.78 billion over the same period in 2008 and the lowest quarterly investment total since 1998. Only 477 venture deals were completed in the period, well below the 706 deals done in the first quarter last year and the industry's lowest quarterly deal total since 1996.
"We're seeing continued retrenching in the venture capital industry," said Jessica Canning, director of global research for Dow Jones VentureSource. "Over the past several quarters, VCs have pulled back significantly on early-stage investments in the USA, across all industries. During the economic downturn, investors will continue to focus on nurturing their strongest, existing portfolio companies, and keep their eyes open for the next set of opportunities."
Health care sees smallest drop
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze